MedTrace Logo

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

NCT05767528 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-03-14

No results posted yet for this study

Summary

In this study, investigators plan to conduct the 3D in vitro culture PTC drug sensitivity testing of fresh tumor specimen which obtained by endoscopic biopsy or other methods. Through assessing the consistency between the testing results and the patients' neoadjuvant treatment outcomes, they would evaluate the accuracy of PTC drug sensitivity testing and its application value in the individualized precision medicine for muscle-invasive bladder carcinoma.

Conditions

  • Muscle-Invasive Bladder Carcinoma

Interventions

DIAGNOSTIC_TEST

Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing

Conducting the neoadjuvant therapy of FDA-approved drugs for patients with muscle-invasive bladder carcinoma, culturing the patient-derived tumor-like cell clusters for drug sensitivity testing simultaneously, then assess the accuracy of the diagnostic test by combination and analysis of these results

Sponsors & Collaborators

  • Beijing GeneX Health Technology Co., Ltd

    collaborator UNKNOWN

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Xu Zhang, M.D.&Ph.D. · Chinese PLA General Hospital

  • Hongzhao Li, M.D.&Ph.D. · Chinese PLA General Hospital

  • Shaoxi Niu, M.D.&Ph.D. · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-08
Primary Completion
2023-12-08
Completion
2024-12-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05767528 on ClinicalTrials.gov